Recent Advances in Understanding the Molecular Mechanisms of Tamoxifen Action

References

• Butta A, MacLennan K, Flanders K C, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261–4264
   PubMed Web of Science ®Google Scholar
• Charlier C, Colin C, Merville M P, et al. [Tamoxifen in the treatment of breast cancer]. J Gynecol Obstet Biol Reprod (Paris) 1994; 23: 751–756
   PubMedGoogle Scholar
• Gagliardi A, Collins D C. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993; 53: 533–535
   PubMed Web of Science ®Google Scholar
• Jordan V C. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 1993; 110: 507–517
   PubMed Web of Science ®Google Scholar
• Jordan V C. A current view of tamoxifen for the treatment and prevention of breast cancer. (Gaddum Memorial Lecture). Br J Pharmacol 1993; 110: 507–517
   PubMed Web of Science ®Google Scholar
• Jordan V C. Third annual William L. McGuire Memorial Lecture. Studies on the estrogen receptor in breast cancer–20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995; 36: 267–285
   PubMed Web of Science ®Google Scholar
• Mulshine J L, Jett M, Cuttita F, et al. Scientific basis for cancer prevention. Intermediate cancer markers. Cancer 1993; 72(Suppl 3)978–983
   PubMed Web of Science ®Google Scholar
• Nayfield S G. Tamoxifen's role in chemoprevention of breast can-Molecular Mechanisms of Tamoxifen Action cer: An update. J Cell Biochem 1995; 22(Suppl)42–50
   Google Scholar
• Baral E, Nagy E, Berczi I. Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol. Cancer 1995; 75: 591–599
   PubMed Web of Science ®Google Scholar
• Charlier C, Chariot A, Antoine N, et al. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol 1995; 49: 351–358
   PubMed Web of Science ®Google Scholar
• Croxtall J D, Emmas C, White J O, et al. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem Pharmacol 1994; 47: 197–202
   PubMed Web of Science ®Google Scholar
• Grenman S E, Worsham M J, Van D D, et al. Establishment and characterization of UM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line. Gynecol Oncol 1990; 37: 188–199
   PubMed Web of Science ®Google Scholar
• Howe S R, Pass H I, Ethier S P, et al. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen. Cancer Res 1996; 56: 4049–41055
   PubMed Web of Science ®Google Scholar
• Zajchowski D A, Sager R, Webster L. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor. Cancer Res 1993; 53: 5004–5011
   PubMed Web of Science ®Google Scholar
• Chakravarty N. The roles of calmodulin and protein kinase C in histamine secretion from mast cells. Agents Actions 1992; 36: 183–191
   PubMedGoogle Scholar
• Colletta A A, Benson J R, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 1994; 31: 5–9
   PubMed Web of Science ®Google Scholar
• Lam H Y. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 1984; 118: 27–32
   PubMed Web of Science ®Google Scholar
• Lopes M C, Vale M G, Carvalho A P. Ca2+-dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res 1990; 50: 2753–2758
   PubMed Web of Science ®Google Scholar
• Mac N S, Wagner M, Kirkham P R, et al. Inhibition of melanoma cell/matrix interaction by tamoxifen. Melanoma Res 1993; 3: 67–74
   PubMed Web of Science ®Google Scholar
• Mac N S, Dawson R A, Crocker G, et al. Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity. Br J Dermatol 1993; 128: 143–150
   PubMed Web of Science ®Google Scholar
• Pan Z, Radding W, Zhou T, et al. Role of calmodulin in HIV-potentiated Fas-mediated apoptosis. Am J Pathol 1996; 149: 903–910
   PubMed Web of Science ®Google Scholar
• Sutherland R L, Watts C K, Hall R E, et al. Mechanisms of growth inhibition by nonsteroidal antioestrogens in human breast cancer cells. J Steroid Biochem 1987; 27: 891–897
   PubMedGoogle Scholar
• Wiseman H. Tamoxifen:new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 1994; 15: 83–89
   PubMed Web of Science ®Google Scholar
• Colletta A A, Wakefield L M, Howell F V, et al. Anti-oestrogens induce the secretion of active transforming factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 405–4109
   PubMed Web of Science ®Google Scholar
• Knabbe C, Zugmaier G, Schmahl M, et al. Induction to transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am J Clin Oncol 1991; 14(Suppl2)S15–20
   PubMedGoogle Scholar
• Knabbe C, Kopp A, Hilgers W, et al. Regulation and role of TGF beta production in breast cancer. Ann NY Acad Sci 1996; 784: 263–276
   PubMed Web of Science ®Google Scholar
• Kang Y, Cortina R, Perry R R. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst 1996; 88: 279–284
   PubMed Web of Science ®Google Scholar
• Rochefort H. Oestrogen- and anti-oestrogen-regulated genes in human breast cancer. Ciba Found Symp 1995; 191: 254–265
   PubMedGoogle Scholar
• Laurence J, Cooke H, Sikder S K. Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1. Blood 1990; 75: 696–703
   PubMed Web of Science ®Google Scholar
• Lim J S, Frenkel K, Troll W. Tamoxifen suppresses tumor promoter-induced hydrogen peroxide formation by human neutrophils. Cancer Res 1992; 52: 4969–4972
   PubMed Web of Science ®Google Scholar
• Moraru I I, Laky M, Stanescu T, et al. Protein kinase C controls Fc gamma receptor-mediated endocytosis in human neutrophils. FEBS Lett 1990; 274: 93–95
   PubMed Web of Science ®Google Scholar
• Pollack I F, Randall M S, Kristofik M P, et al. Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. Cancer Res 1990; 50: 7134–7138
   PubMed Web of Science ®Google Scholar
• O'Brian C A, Ward N E, Anderson B W. Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J Natl Cancer Inst 1988; 80: 1628–1633
   PubMed Web of Science ®Google Scholar
• O'Brian C A, Liskamp R M, Solomon D H, et al. Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 1986; 76: 1243–1246
   PubMed Web of Science ®Google Scholar
• Friedman Z Y. The anti-tumor agent tamoxifen inhibits breakdown of polyphosphoinositides in GH4Cj cells. J Pharmacol Exp Ther 1994; 271: 238–245
   PubMed Web of Science ®Google Scholar
• Friedman Z Y. Tamoxifen and vanadate synergize in causing accumulation of polyphosphoinositides in GH4C, membranes. J Pharmacol Exp Ther 1993; 267: 617–623
   PubMed Web of Science ®Google Scholar
• Berridge M J. Inositol lipids and cell proliferation. Biochim Biophys Acta 1987; 907: 33–45
   PubMed Web of Science ®Google Scholar
• McDonald C C, Stewart H J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 1991; 303: 435–437
   PubMed Web of Science ®Google Scholar
• Wiseman H, Quinn P, Halliwell B. Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions?. FEBS Lett 1993; 330: 53–56
   PubMed Web of Science ®Google Scholar
• Wiseman H, Paganga G, Rice E C, et al. Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: A mechanism accounting for the cardioprotective action of tamoxifen. Biochem J 1993; 292: 635–638
   PubMed Web of Science ®Google Scholar
• Wiseman H, Quinn P. The antioxidant action of synthetic oestro-gens involves decreased membrane fluidity: relevance to their potential use as anticancer and cardioprotective agents compared to tamoxifen. Free Radic Res 1994; 21: 187–194
   PubMed Web of Science ®Google Scholar
• Love R R, Wiebe D A, Newcomb P A, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115: 860–864
   PubMed Web of Science ®Google Scholar
• Berridge M J. Inositol triphosphate and diacylglycerol: Two interacting second messengers. Annu Rev Biochem 1987; 56: 159–193
   PubMed Web of Science ®Google Scholar
• Cockroft S. Phosphoinositide phosphodiesterase: regulation by a novel guanine nucleotide binding protein Gp. Trends Biochem Sci 1987; 12: 75–78
   Web of Science ®Google Scholar
• Boyer J L, Hepler J R, Harden T K. Hormone and growth factor-mediated regulation of phospholipase C activity. Trends Pharmacol Sci 1989; 10: 360–364
   PubMed Web of Science ®Google Scholar
• Margolis B, Rhee S G, Felder S, et al. EGF induces tyrosine phosphorylation of phospholipase C-II: A potential mechanism for EGF receptor signaling. Cell 1989; 57: 1101–1107
   PubMed Web of Science ®Google Scholar
• Meisenhelder J, Suh P-G, Rhee S G, et al. Phosphlipase C-gamma is a substrate for the PDGF and EGF receptor protein kinases in vivo and in vitro. Cell 1989; 57: 1109–1122
   PubMed Web of Science ®Google Scholar
• Wahl M I, Nishibe S, Suh P-G, et al. Epidermal growth factor stimulates tyrosine phosphorylation of phospholipase C-II independently of receptor internalization and extracellular calcium. Proc Natl Acad Sci USA 1989; 86: 1568–1572
   PubMed Web of Science ®Google Scholar
• Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203–212
   PubMed Web of Science ®Google Scholar
• Smith M R, Ryu S H, Suh P-G, et al. S-phase induction and transformation of quiescent NIH3T3 cells by micrinjection of phos-pholipase C. Proc Natl Acad Sci USA 1989; 86: 3659–3663
   PubMed Web of Science ®Google Scholar
• Gorga F R, Riney C E, Benjamin T L. Inositol triphosphate levels in cells expressing wild-type and mutant polyomavirus middle T antigens: Evidence for activation of phospholipase C via activation of pp60c-src. J Virol 1990; 64: 105–112
   PubMed Web of Science ®Google Scholar
• Sesko A, Cabot M, Mossman B. Hydrolysis of inositol phospholipids precedes cellular proliferation in asbestos-stimulated tracheobronchial epithelial cells. Proc Natl Acad Sci USA 1990; 87: 7385–7389
   PubMed Web of Science ®Google Scholar
• Talwar H S, Fisher G J, Voorhees J J. Bradykinin induces phospho-inositide turnover, 1,2-diacylglyceride formation and growth in cultured adult keratinocytes. J Invest Dermatol 1990; 95: 705–710
   PubMed Web of Science ®Google Scholar
• Tilly B C, Tertoolen L G, Remorie R, et al. Histamine as a growth factor an chemoattractant for human carcinoma and melanoma cells: action through Ca2+-mobilizing HI receptors. J Cell Biol 1990; 110: 1211–1215
   PubMed Web of Science ®Google Scholar
• Lucas D O, Bajjalieh S M, Kowalchyk J A, et al. Direct stimulation by thyrotropin-releasing hormone (TRH) of polyphosphoinositide hydrolysis in GH3 cell membranes by a guanine nucleotide-modulated mechanism. Biochem Biophys Res Commun 1985; 132: 721–728
   PubMed Web of Science ®Google Scholar
• Martin T FJ, Bajjalieh S M, Lucas D O, et al. Thyrotopin-releasing hormone stimulation of polyphosphoinositdes hydrolysis in GH3 cell membranes is GTP dependent but insensitive to cholera or pertussis toxin. J Biol Chem 1986; 261: 10141–10149
   PubMedGoogle Scholar
• Straub R E, Gershengorn M C. Thyrotopin-releasing hormone and GTP activate inositol trisphosphate formation in membranes isolated from rat pituitary cells. J Biol Chem 1986; 261: 2712–2717
   PubMed Web of Science ®Google Scholar
• Martin T FJ, Kowalchyk J A. Reconstruction of a solubilized membrane but not cytosolic phospholipase C with membrane-associated Gp from GH3 cells. J Biol Chem 1989; 264: 20917–20922
   PubMed Web of Science ®Google Scholar
• Pachter J A, Law G J, Dannies P S. Bombesin stimulates inositol polyphosphate production in GH4C[ rat pituitary cells: Demonstration of guanyl nucleotide sensitivity. Biochem Biophys Res Commun 1988; 154: 654–659
   PubMedGoogle Scholar
• Fischer J B, Schonbrunn A. The bombesin receptor is coupled to a guanyl nucleotide binding protein which is insensitive to pertussis and cholera toxins. J Biol Chem 1988; 263: 2808–2816
   PubMed Web of Science ®Google Scholar
• Allan D, Michell R H. Phosphatidylinositol cleavage catalysed by the soluble fraction from lymphocytes. Biochem J 1974; 142: 591–597
   PubMedGoogle Scholar
• Harwood J L, Hawthorne J N. The properties and subcellular distribution of phosphatidylinositol kinases in mammalian tissues. Biochim Biophys Acta 1969; 171: 75–88
   PubMed Web of Science ®Google Scholar
• Endemann G, Dunn S N, Cantley L C. Bovine brain contains two types of phosphatidylinositol kinase. Biochemistry 1987; 26: 6845–6852
   PubMed Web of Science ®Google Scholar
• Whitman M, Kaplan D, Roberts T, et al. Evidence for two distinct phosphatidylinositol kinases in fibroblasts. Biochem J 1987; 247: 165–174
   PubMed Web of Science ®Google Scholar
• Kai M, Salway J G, Hawthorne J N. The diphosphoinositide kinase of rat brain. Biochem J 1968; 106: 791–797
   PubMed Web of Science ®Google Scholar
• Cochet C, Chambaz E M. Catalytic properties of a purified phos-phatidylinositol-4-phosphate kinase from rat brain. Biochem J 1986; 237: 25–31
   PubMed Web of Science ®Google Scholar
• Ling L E, Schulz J T, Cantley L C. Characterization and purification of membrane-associated phosphatidylinositol-4-phosphate kinase from human red blood cells. J Biol Chem 1989; 264: 1580–5088
   Google Scholar
• Van Dongen C J, Zwiers H, Gipsen W H. Purification and partial characterization of the phosphatidylinositol 4-phosphate kinase from rat brain. Biochem J 1984; 223: 197–203
   PubMed Web of Science ®Google Scholar
• Jarvis W D, Judd A M, MacLeod R M. Attenuation of anterior pituitary phosphoinositide phosphorylase activity by the D2 dopamine receptor. Endocrinology 1988; 123: 2793–2799
   PubMed Web of Science ®Google Scholar
• Urumow T, Wieland O H. Evidence for a cholera-toxin-sensitive G-protein involved in the regulation of phosphatidylinositol-4-phosphate kinase of rat liver membranes. Biochim Biophys Acta 1988; 972: 232–238
   PubMed Web of Science ®Google Scholar
• Urumow T, Wieland O H. A small G-protein involved in phos-phatidylinositol-4-phosphate kinase activation. FEBS Lett 1990; 263: 15–17
   PubMed Web of Science ®Google Scholar
• Smith C D, Chang K J. Regulation of brain phosphatidylinositol-4-phosphate kinase by GTP analogues. A potential role for guanine nucleotide regulatory proteins. J Biol Chem 1989; 264: 3206–3210
   PubMed Web of Science ®Google Scholar
• Pike M C, Costello K M, Lamb K A. IL-8 stimulates phos-phatidylinostitol-4-phosphate kinase in human polymorphonuclear leukocytes. J Immunol 1992; 148: 3158–3164
   PubMed Web of Science ®Google Scholar
• Pike M C, Costello K, Southwick F S. Stimulation of human polymorphonuclear leukocytes phosphatidylinositol-4-kinase by con-canavalin A and formyl-methionyl-leucyl-phenylalanine is calcium-independent. Correlation with maintenance of actin assembly. J Immunol 1991; 147: 2270–2275
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ohsugi K, Ono Y. EB V increases phosphoinositide kinase activities in human B cells. J Immunol 1992; 149: 207–213
   PubMed Web of Science ®Google Scholar
• Ballou L R, Barker S C, Postlethwaite A E, et al. Interleukin-1 stimulates phosphatidylinositol kinase activity in human fibroblasts. J Clin Invest 1991; 87: 299–304
   PubMed Web of Science ®Google Scholar
• Cochet C, Filhol O, Parastre B, et al. Interaction between the epidermal growth factor receptor and phosphoinositide kinases. J Biol Chem 1991; 266: 637–644
   PubMed Web of Science ®Google Scholar
• Michell R H, Harwood J L, Coleman R, et al. Characteristics of rat liver phosphatidylinositol kinase and its presence in the plasma membrane. Biochim Biophys Acta 1967; 144: 649–658
   PubMed Web of Science ®Google Scholar
• MacDonald M L, Kuenzel E A, Glomset J A, et al. Evidence from two transformed cell lines that the phosphorylations of peptide tyrosine and phosphatidylinositol are catalysed by different proteins. Proc Natl Acad Sci USA 1985; 82: 3993–3997
   PubMed Web of Science ®Google Scholar
• van Rooijen L LA, Rossovska M, Bazan N G. Inhibition of phos-phatidylinositol-4-phosphate kinase by its product phosphatidyli-nositol-4,5-bisphosphate. Biochem Biophys Res Commun 1985; 126: 150–155
   PubMed Web of Science ®Google Scholar
• Rao U S, Fine R L, Scarborough G A. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 1994; 48: 287–292
   PubMed Web of Science ®Google Scholar
• Callaghan R, Higgins C F. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 1995; 71: 294–299
   PubMed Web of Science ®Google Scholar